Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of eliglustat versus Cerezyme in stable Gaucher disease type 1 after enzyme replacement therapy
2008-005223-28Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jul 2009
- Modality
- Small Molecules, Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Gaucher disease type 1 (GD1) comparing Eliglustat with Cerezyme (2 arms). Primary endpoint: Percentage of patients remaining stable at 52 weeks. Started Jul 2009; status: completed.
02
Drugs
eliglustatimiglucerase
03
Conditions
Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on 2008-005223-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005223-28.